| 貨號 | 規格 | 價格 | 上海 | 北京 | 武漢 | 南京 | 購買數量 |
|---|---|---|---|---|---|---|---|
S85925-1mg |
99.0% | ￥70.00 | 7 | - | - | - |
|
S85925-2mg |
99.0% | ￥120.00 | 6 | - | - | - |
|
S85925-5mg |
99.0% | ￥170.00 | 8 | - | - | - |
|
S85925-10mg |
99.0% | ￥260.00 | 7 | - | - | - |
|
S85925-25mg |
99.0% | ￥510.00 | 5 | - | - | - |
|
S85925-50mg |
≥99% | ￥880.00 | 貨期：2-3天 | - | - | - |
|
S85925-100mg |
≥99% | ￥1490.00 | 貨期：2-3天 | - | - | - |
|
Azeliragon (TTP488) is an orally bioavailable inhibitor of the receptor for advanced glycation end products (RAGE) in development as a potential treatment to slow disease progression in patients with mild Alzheimer’s disease (AD). Azeliragon also can cross the blood-brain barrier (BBB)
| 產品描述： | Azeliragon (TTP488) is an orally bioavailable inhibitor of the receptor for advanced glycation end products (RAGE) in development as a potential treatment to slow disease progression in patients with mild Alzheimer’s disease (AD). Azeliragon also can cross the blood-brain barrier (BBB) | ||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 靶點： | Amyloid-β;BetaAmyloid;advancedglycationendproducts | ||||||||||||||||||||
| 體內研究： | Azeliragon (100 mcg/d; intraperitoneal injection; every day) treatment reduces syngeneic islet graft and islet allograft in NOD and B6 mice (Islets were isolated from young prediabetic NOD/LtJ mice and transplanted into NOD mice with spontaneous diabetes; islets were isolated from WT BALB/c mice and transplanted into B6 mice with diabetes) | ||||||||||||||||||||
| 參考文獻： | 1. Burstein AH, et al. Assessment of Azeliragon QTc Liability Through Integrated, Model-Based Concentration QTc Analysis. Clin Pharmacol Drug Dev. 2019 May;8(4):426-435. 2. Bongarzone S, et al. Targeting the Receptor for Advanced Glycation Endproducts (RAGE): A Medicinal Chemistry Perspective. J Med Chem. 2017 Sep 14;60(17):7213-7232. 3. Chen Y, et al. RAGE ligation affects T cell activation and controls T cell differentiation. J Immunol. 2008 Sep 15;181(6):4272-8. | ||||||||||||||||||||
| 溶解性： | Soluble in DMSO | ||||||||||||||||||||
| 保存條件： | RT | ||||||||||||||||||||
| 配置溶液濃度參考： |
|
||||||||||||||||||||
| 注意： | 部分產品我司僅能提供部分信息，我司不保證所提供信息的權威性，僅供客戶參考交流研究之用。 |
上海工商
滬公網安備 31011702002021號
危險品化學品經營許可證（不帶存儲）
營業執照(三證合一)
北京